## 

## FIG. 1A

	-42" -20" -12 to to to	_		2	1	- - -	) - -	2											
	-3 -3		-	0	6.	4	5	6 7	-			-	-	-			+-+	<b>↓</b>	*
Week of Study								1 2	က	4	5	9	2	∞	တ	9	7	12	
Month of Study		-	+	-	-								-	-+		_	-		
Surgery										+	_	-			_		-	-	
nformed Consent	×:	1	:								<u>!</u>	<u> </u>		+			+		
Randomize	<b>×</b>		1		+	+-	+	+-	+	+	+	-	-	-					
Cyclophosphamide		:	×	×	X A	<u> </u>	X	$\frac{\times}{0}$	<u>.</u> 0				XC	:	-	-			
BCG		-		<u> </u>	>	)   	   	×	  ×	-		-	×						
/accine		<b>&lt;</b>		< >	< >	< >	< >	<   ×	X	9	Xe	(e)	Xe Xe Xe Xe Xe	(e)	×	×	e Xe	Xe	*
History/Physical Exam	×	× :		< >	< >	< >	< >	< >	\	X	XP	Xe	×e	×e×	Xe Xe	×	×	Xe Xe Xe	*
Vital Signs	×	×		<b>×</b>  >	< >	< >	< >	< >	<   ×	٥	X	Xe	×e		(e)	×	e Xe	e Xe	*
Performance Status	×	× :		< >	< >	< >	<	<del> </del>	\ ` { ×	X		Xe	Xe	×e	×e×	Xe Xe	e Xe	e Xe	*
Routine Labs **	×	×		<	<	<	<	<	<del>`</del>	2	-			+-	-				
Pregnancy (HCG)	×					$\top$	+		+		+	+	-	+	-	-	-		
Hepatitis/HIV	×								-		Xe	+-	+-	+	Xe	×	Xe		*
Chest X-Ray		_	_						+-	+-	+-		Xe		-			×e	* 0

## FIG. IB

Ø

Þ

This can be extended up to -56 days only if an additional procedure is needed to establish that the

patient is melanoma-free prior to randomization

History/Physical Exam, Vital Signs, Performance Status, Routine Labs, Chest X-Ray q2 months in year 2, q3 months in year 3, then q6 months through year 5; CT or MRI at 18, 24, and 36 months (chest x-ray omitted if CT/MRI scheduled)

0.1mL of a 1:10 dilution of Tice BCG (Tice-A) mixed with vaccine

0.1 mL of a 1:100 dilution of Tice BCG (Tice-B) mixed with vaccine

0.1 mL of a 1:1000 dilution of Tice BCG (Tice-C) mixed with vaccine

X XB

This can be extended up to -34 days if an additional procedure is needed to establish that the patient is melanoma-free prior to randomization

Routine Labs: hematology (CBC with differential, platelet count), BUN or creatinine, LDH, SGOT, alkaline phosphatase, electrolytes

e End of Treatment Month